Caribou Biosciences (CRBU) Interest & Investment Income (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Interest & Investment Income of -$126000.0 for Q1 2026, down 43.18% year-over-year from -$221760.0 in Q1 2025, and down 1360.0% quarter-over-quarter from $10000.0 in Q4 2025.
Caribou Biosciences (CRBU) Interest & Investment Income (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Interest & Investment Income for 7 consecutive years, with -$126000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 43.18% year-over-year to -$126000.0; the TTM figure through Mar 2026 stood at -$190000.0 (down 138.85% YoY), while the FY2025 annual figure was -$152000.0, down 167.56% from the prior year.
- Interest & Investment Income retreated to -$126000.0 in Q1 2026 per CRBU's latest filing, from $10000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.1 million in Q3 2024 and bottomed at -$954000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $6588.2 across 5 years, with a median of -$88000.0 in 2025.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 614.84% — and 2025, when it plunged 4333.33%.
- Caribou Biosciences' Interest & Investment Income stood at $517000.0 in 2022, then jumped by 95.55% to $1.0 million in 2023, then slumped by 152.82% to -$534000.0 in 2024, then surged by 101.87% to $10000.0 in 2025, then slumped by 1360.0% to -$126000.0 in 2026.
- Business Quant data shows CRBU's Interest & Investment Income at -$126000.0 in Q1 2026, $10000.0 in Q4 2025, and $53000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | -48,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48,000.00 |
| Mar 31, 2026 | -126,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Jun 30, 2025 | -127,000.00 |
| Mar 31, 2025 | -88,000.00 |
| Dec 31, 2024 | -534,000.00 |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | -352,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 155,000.00 |
| Jun 30, 2023 | -406,000.00 |
| Mar 31, 2023 | 788,000.00 |
| Dec 31, 2022 | 517,000.00 |
| Sep 30, 2022 | -454,000.00 |
| Jun 30, 2022 | -492,000.00 |
| Mar 31, 2022 | -954,000.00 |
| Dec 31, 2021 | -135,000.00 |
| Jun 30, 2021 | 46,000.00 |